摘要
目的观察罗格列酮对初发2型糖尿病患者血糖、炎症因子和胰岛素抵抗的影响,从而探讨其控制血糖和改善胰岛素抵抗、抗炎的作用机制。方法选取黑龙江省大庆龙南医院内分泌科2009年1月~2012年1月收治的2型糖尿病患者64例,采用随机数字表法分为观察组(罗格列酮)和对照组(二甲双胍),每组各32例,比较两组治疗前及治疗后12、24周空腹血糖(FBG)、餐后2 h血糖(2 h PG)的水平,糖化血红蛋白(HbA1c)、胰岛素抵抗指数(HOMA-IR)、炎症因子血清白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)的变化情况。结果两组的FBG、2 h PG、HbA1c、HOMA-IR、炎症因子TNF-α、IL-6治疗后12周及治疗后24周均较治疗前明显降低,且治疗后24周较前一时间点治疗后12周也明显降低,且观察组上述指标分别较对照组降低更显著,差异有统计学意义(P<0.05)。结论罗格列酮不仅能降低2型糖尿病患者的血糖水平,还可以减轻机体炎症状态及改善胰岛β细胞的功能,值得广泛推广和应用。
Objective To observe the impact of Rosiglitazone on the blood sugar,inflammatory factors and insulin resistance influence of onset of type 2 diabetes,and further to explore mechanism of the control of blood glucose and improve insulin resistance,anti-inflammatory for type 2 diabetes.Methods 64 cases of patients with type 2 diabetes from January 2009 to January 2012 in Daqing Longnan hospital in Heilongjiang Province were selected,and they were randomly divided into observation group(Rosiglitazone) and the control group(Metformin) according to the random number table,each group had 32 cases.FBG,2 h PG,HbA 1c,HOMA-IR,inflammatory cytokines TNF-α,IL-6 changes in circumstances were compared between the two groups before treatment and after treatment for 12 weeks,24 weeks.Results The FBG,2 h PG,HbA 1c,HOMA-IR,inflammatory cytokines TNF-α,IL-6 after treatment 12 weeks or after treatment 24 weeks in the observation group was significantly lower than before treatment,and those after treatment 24 weeks compared to a previous point in time after 12 weeks of treatment were significantly reduced,and the observation group was reduced more significantly compared with the control group,and there were statistically significant differences(P 0.05).Conclusion Rosiglitazone is not only to reduce blood sugar levels in patients with type 2 diabetes,but also can reduce the inflammatory state and improve the function of pancreatic β cells,which should be popularized and applied.
出处
《中国医药导报》
CAS
2013年第8期19-20,23,共3页
China Medical Herald
基金
黑龙江省自然科学基金项目(项目编号:D201127)
关键词
罗格列酮
2型糖尿病
血糖
胰岛Β细胞
炎症因子
Rosiglitazone
Type 2 diabetes
Blood sugar
Islet β-cells
Inflammatory cytokines